Early and late results of intravenous immunoglobulin as potential adjuvant therapies in critically ill COVID-19 patients: a retrospective cohort study

Year 2022, Volume: 5 Issue: 3, 794 - 798, 30.05.2022

Canan Gürsoy , Özge Oral Tapan , Emrah Doğan , Sinan Pektaş , Semra Demirbilek

https://doi.org/10.32322/jhsm.1036274

Cited By: 1

Abstract

Introduction: Intravenous immunoglobulin (IVIG), which is one of the adjuvant therapy strategies, has been started to be used in critically ill COVID-19 patients due to its anti-inflammatory and immunomodulatory effects.
Material and Method: In our study, it was aimed to evaluate the effect of IVIG used in critically ill COVID-19 patients in the intensive care unit on early laboratory findings and late lung damage. Twenty-two critically ill COVID-19 patients who met the inclusion criteria were included in the study. Laboratory data of the patients who received 0.4 gr/kg/day IVIG for 5 days were analyzed before the treatment and on the 1st and 5th days of the treatment. For the percentage of injured lung areas was evaluated with chest CT.
Results: Respiratory rate and CRP decreased with IVIG, while an increase was observed in PaO2/FiO2, WBC, lymphocyte count, D-Dimer and fibrinogen values, which was statistically significant (p<0.05). When IL-6 values before treatment and on the 3rd day of treatment were compared, it was observed that there was a statistically significant decrease (p<0.001). A statistically significant improvement in lung damage was found when the average percentage of injured lung area calculated from chest CT taken at hospitalization and 1 month after discharge was compared (p<0.001).
Conclusion: IVIG can be considered as an effective adjuvant therapy because it causes improvement in oxygenation, clinical symptoms and hyperinflammatory response. It should not be forgotten that it also provides improvement in the damaged lung areas in the late period.

Keywords

COVID-19, Immunoglobulin, IVIG, Pneumonia

References

• Grasselli G, Greco M, Zanella A, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med 2020; 180: 1345-55.
• Salian VS, Wright JA, Vedell PT, et al. COVID-19 Transmission, current treatment, and future therapeutic strategies. Mol Pharm 2021; 18: 754-71.
• Liu X, Cao W, Li T. High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects. Front Immunol 2020; 11: 1660.
• Sakoulas G, Geriak M, Kullar R, et al. Intravenous Immunoglobulin (IVIG) significantly reduces respiratory morbidity in COVID-19 pneumonia: a prospective randomized trial. medRxiv 2020; 20157891.
• Herth FJF, Sakoulas G, Haddad F. Use of intravenous immunoglobulin (Prevagen or Octagam) for the treatment of COVID-19: retrospective case series. Respiration 2020; 99: 1145-53.
• Raman RS, Bhagwan Barge V, Anil Kumar D, et al. A Phase II safety and efficacy study on prognosis of moderate pneumonia in coronavirus disease 2019 patients with regular intravenous immunoglobulin therapy. J Infect Dis 2021; 223: 1538-43.
• Çolak M, Kalemci S, Sarıhan A. Treatment of a case with COVID-19 administering intravenous immunoglobulin. J Glob Antimicrob Resist 2020; 24: 106-7.
• Suzuki Y, Tanino Y, Nikaido T, et al. Severe coronavirus disease 2019 that recovered from respiratory failure by treatment that included high-dose intravenous immunoglobulin. Intern Med 2021; 60: 457-61.
• Tatar E, Karatas M, Bozaci I, et al. Intravenous immunoglobulin and favipiravir treatment for a kidney transplant patient with severe COVID-19 pneumonia. Transfus Apher Sci 2020; 59: 1-3.
• Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of intravenous immunoglobulin (IVIg) on the management of severe COVID-19 cases: a randomized controlled trial, Int Immunopharmacol 2021; 90: 107205.
• Shao Z, Feng Y, Zhong L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunol 2020; 9: 1-10.
• Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 2020; 20: 1-8.
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis 2020; 7: 1-6.
• Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host & Microbe 2020; 27: 992-1000.
• Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract 2021; 75: 1-5.